Infringement Claims Nixed In Focalin Patent Suits
Continuing a trend in Focalin patent litigation, a federal judge has tossed claims for willful infringement from two actions filed by Celgene Corp. and Novartis Pharmaceuticals Corp. to block generic versions...To view the full article, register now.
Already a subscriber? Click here to view full article